Zelapar

Zelapar is a brand name of selegiline, approved by the FDA in the following formulation(s):

ZELAPAR (selegiline hydrochloride - tablet, orally disintegrating; oral)

• 
  Manufacturer: VALEANT PHARM INTL
  
  Approval date: June 14, 2006
  
  Strength(s): 1.25MG ^[RLD]

Has a generic version of Zelapar been approved?

No. There is currently no therapeutically equivalent version of Zelapar available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zelapar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmaceutical and other dosage forms
  Patent 5,648,093
  Issued: July 15, 1997
  Inventor(s): Gole; Dilip J. & Levinson; R. Saul & Wilkinson; Paul K. & Davies; J. Desmond
  Assignee(s): Janssen Pharmaceutica Inc.
  A fast dissolving, solid dosage form defined by a matrix containing gelatin, pectin and/or soy fiber protein and one or more amino acids having from about 2 to 12 carbon atoms is disclosed.
  
  Patent expiration dates:
  
  
  • July 15, 2014
    
    ✓ 
    Drug product
  
  



• 
  Process for the preparation of a solid pharmaceutical dosage form
  Patent 6,423,342
  Issued: July 23, 2002
  Inventor(s): Andrew William; Jordan & Joy Elaine; Saunders & Patrick; Kearney
  Assignee(s): R. P. Scherer Corporation
  A process for the preparation of a solid pharmaceutical dosage form comprising a carrier and, as active ingredient, a compound which exists, in solution, in an equilibrium between a free acid or free base form and a salt form, and for which there is a difference in volatility between the free acid or free base form and the salt form. The process includes the steps of solidifying a mixture of the compound and carrier in a solvent, and subsequently removing the solvent from the solidified mixture. A pH modifier is added to the mixture prior to solidification to shift the equilibrium to favor the less volatile form of the active ingredient.
  
  Patent expiration dates:
  
  
  • March 1, 2016
    
    ✓ 
    Drug product
  
  

See also...

• Zelapar Consumer Information (Drugs.com)
• Zelapar Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Zelapar Consumer Information (Cerner Multum)
• Zelapar Advanced Consumer Information (Micromedex)
• Selegiline Consumer Information (Wolters Kluwer)
• Selegiline Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Selegiline System Consumer Information (Wolters Kluwer)
• Selegiline Consumer Information (Cerner Multum)
• Selegiline transdermal Consumer Information (Cerner Multum)
• Selegiline Advanced Consumer Information (Micromedex)
• Selegiline Transdermal Advanced Consumer Information (Micromedex)
• Selegiline Hydrochloride AHFS DI Monographs (ASHP)